title: Synergies of microtissue design, viral transduction and adjustable transgene expression for regenerative medicine.
abstract: In the past decade, regenerative medicine has evolved as an interdisciplinary field, integrating expertise from the medical, life- and material-science communities. Recent advances in tissue engineering, gene therapy, gene-function analysis, animal-free drug testing, drug discovery, biopharmaceutical manufacturing and cell-phenotype engineering have capitalized on a core technology portfolio including artificial microtissue design, viral transduction and precise transcription dosing of therapeutic or phenotype-modulating transgenes. We provide a detailed overview on recent progress in these core technologies and comment on their synergistic impact on current and future human therapies.
authors.affiliation: Institute of Biotechnology, Swiss Federal Institute of Technology, ETH Hoenggerberg, HPT, CH-8093 Zurich, Switzerland.
authors.forename: Jens M
authors.initials: JM
authors.lastname: Kelm
authors.forename: Beat P
authors.initials: BP
authors.lastname: Kramer
authors.forename: Valeria
authors.initials: V
authors.lastname: Gonzalez-Nicolini
authors.forename: Bettina
authors.initials: B
authors.lastname: Ley
authors.forename: Martin
authors.initials: M
authors.lastname: Fussenegger
mesh_terms: D000818:Animals; D005786:Gene Expression Regulation; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D044968:Regenerative Medicine / Q000379:methods*; D023822:Tissue Engineering / Q000379:methods*; D014161:Transduction, Genetic / Q000379:methods; D019076:Transgenes / Q000235:genetics; D014780:Viruses / Q000235:genetics